Literature DB >> 26119857

Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia.

Daniel Mekonnen1, Aschalew Admassu2, Wondemagegn Mulu3, Aranzazu Amor4, Agustín Benito4, Woynshet Gelaye2, Fantahun Biadglegne3, Bayeh Abera3.   

Abstract

BACKGROUND: The prevalence of multidrug-resistant tuberculosis (TB) among new and retreatment cases in 2011 in Ethiopia was 2.7% and 17.9%, respectively. However, data on heteroresistance and gene mutation profiles of Mycobacterium tuberculosis were not documented.
METHODS: A cross-sectional study was conducted on 413 TB-positive clinical specimens submitted between 2012 and 2014 to Bahir Dar Regional Laboratory Center for confirmation of multidrug resistance. Resistance determining genes were analyzed using a line probe assay.
RESULTS: Of 413M. tuberculosis isolates, 150 (36.3%) were multidrug-resistant, 19 (4.6%) were resistant only to rifampicin, and 26 (6.3%) were resistant to isoniazid. Of 169 rifampicin-resistant and 176 isoniazid-resistant isolates, only eight (4.7%) showed rifampicin heteroresistance and only two (1.13%) showed isoniazid heteroresistance. Failing of the rpoB WT8 gene with corresponding hybridization of rpoB MUT3 (S531L substitution) accounted for 85 (50.3%) rifampicin-resistant mutations. Among 176 isoniazid-resistant isolates, 155 (88.1%) strains had the Ser315Thr1 substitution.
CONCLUSIONS: The prevalence of multidrug-resistant M. tuberculosis was high in the study area. Ser531Leu and Ser315Thr1 substitutions were the highest gene mutations for rifampicin and isoniazid, respectively.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Ethiopia; Gene mutations; Heteroresistance; Multidrug-resistant tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26119857     DOI: 10.1016/j.ijid.2015.06.013

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  10 in total

1.  Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.

Authors:  Soumitesh Chakravorty; Sandy S Roh; Jennifer Glass; Laura E Smith; Ann Marie Simmons; Kevin Lund; Sergey Lokhov; Xin Liu; Peng Xu; Guolong Zhang; Laura E Via; Qingyu Shen; Xianglin Ruan; Xing Yuan; Hong Zhu Zhu; Ekaterina Viazovkina; Shubhada Shenai; Mazhgan Rowneki; Jong Seok Lee; Clifton E Barry; Qian Gao; David Persing; Robert Kwiatkawoski; Martin Jones; Alexander Gall; David Alland
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

2.  Genotypic and phenotypic drug-resistance detection and prevalence of heteroresistance in patients with isoniazid- and multidrug-resistant tuberculosis in Ethiopia.

Authors:  Muluwork Getahun; Gobena Ameni; Helina Mollalign; Getu Diriba; Dereje Beyene
Journal:  IJID Reg       Date:  2022-01-02

3.  Trends of Mycobacterium tuberculosis and rifampicin resistance in Adigrat General Hospital, Eastern zone of Tigrai, North Ethiopia.

Authors:  Getachew Kahsu Abay; Bahlbi Hailay Abraha
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-08-28

4.  Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study.

Authors:  Wondemagegn Mulu; Bayeh Abera; Mulat Yimer; Tadesse Hailu; Haimanot Ayele; Dereje Abate
Journal:  BMC Res Notes       Date:  2017-01-03

5.  Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia.

Authors:  Biresaw Demile; Amare Zenebu; Haile Shewaye; Siqing Xia; Awoke Guadie
Journal:  BMC Infect Dis       Date:  2018-05-31       Impact factor: 3.090

6.  Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR.

Authors:  Hossein Kazemian; Jalil Kardan-Yamchi; Abbas Bahador; Shadi Khonsari; Mahshid Nasehi; Gholamreza Hamzehloo; Farzam Vaziri; Mohammad Reza Salehi; Mohammad Mehdi Feizabadi
Journal:  Infect Drug Resist       Date:  2019-11-15       Impact factor: 4.003

Review 7.  Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis.

Authors:  Mao Ye; Wen Yuan; Leila Molaeipour; Khalil Azizian; Alireza Ahmadi; Ebrahim Kouhsari
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-10-13       Impact factor: 3.944

8.  Proportion and trend of primary resistance among Multidrug resistant Tuberculosis patients in Ethiopia.

Authors:  Adamu Bayissa; Meaza Demissie; Mulatu Biru; Zenebe Akalu
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-04-25

9.  Performance of MTBDRplus assay in detecting multidrug resistant tuberculosis at hospital level.

Authors:  Abebaw Kebede; Daniel Demisse; Meazashwork Assefa; Zerihun Getachew; Bazezew Yenew; Yared Tedla; Gobena Ameni
Journal:  BMC Res Notes       Date:  2017-12-01

10.  Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar.

Authors:  Yunhee Chang; Seoyong Kim; Yeun Kim; Phyu Win Ei; Dasom Hwang; Jongseok Lee; Chulhun L Chang; Hyeyoung Lee
Journal:  Ann Lab Med       Date:  2020-03       Impact factor: 3.464

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.